NCT06438367View on ClinicalTrials.gov

TGRX-326 Pharmacokinetic Mass Balance

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 26, 2024

Primary Completion Date

July 8, 2024

Study Completion Date

July 21, 2024

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

[14C]TGRX-326

Healthy subjects will be given TGRX-326 60 mg orally on day 1.

Trial Locations (1)

215006

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

The First Affiliated Hospital of Soochow University

OTHER

lead

Shenzhen TargetRx, Inc.

INDUSTRY

NCT06438367 - TGRX-326 Pharmacokinetic Mass Balance | Biotech Hunter | Biotech Hunter